Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia
- PDF / 129,862 Bytes
- 2 Pages / 595.276 x 790.866 pts Page_size
- 87 Downloads / 185 Views
LETTER TO THE EDITOR
Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia Mengge Gao 1 & Xiaosu Zhao 1 Received: 1 March 2020 / Accepted: 10 April 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Dear Editor, We have read the letter “Residual disease by flow cytometry in patients with nucleophosmin-mutated acute myeloblastic leukemia” by Marc Sorigue et al. [1]. Thank you very much for your attention to the results of our study [2]. We will make the following analysis for your questions and comments. Multicolor flow cytometry (FCM) has become one of the commonly used methods to monitoring MRD, but sometimes the sensitivity and specificity are still not satisfactory in acute myeloid leukemia (AML) evaluation [3]. However, nucleophosmin 1(NPM1) mutation detection is limited to the probe targets and clonal progression [2]. Thus, we had a hypothesis that these two methods both have certain meaning in prediction and FCM could complement to real-time quantitative polymerase chain reaction (RQ-PCR) for monitoring MRD. Our results were also consistent with this hypothesis. For the questions of Marc et al. [1], we added the data about LAIPs at the newly diagnosis and relapse (Table 1). Our data showed that 43.8% and 49.4% of NPM1 positive patients at the initial diagnosis were CD34 positive and HLA-DR positive, respectively (detailed information in Table 1). Other studies in our institution had further analyzed the immunophenotypes of NPM1-positive patients [4, 5]. Liu et al. in their study found that the positive rates of CD34 and HLA-DR of NPM1-positive AML were higher
* Xiaosu Zhao [email protected] 1
National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Peking University Institute of Hematology, Peking University People’s Hospital, No 11 Xizhimen South Street, Beijing 100044, China
Table 1 Comparison of the immunophenotypes of patients at the newly diagnosis and relapse The newly diagnosis (n = 89)
Relapse (n = 33)
Positive (N)
The positive rate (%)
Positive (N)
The positive rate (%)
HLA-DR CD34 CD64 CD14 CD11b CD15 CD4
44 39 26 15 21 18 2
49.4 43.8 29.2 16.9 23.6 20.2 2.2
17 19 2 0 1 0 0
51.5 57.6 6.1 0 3.0 0 0
CD9 CD10 CD117 CD33 CD13 CD56 CD7 CD19 CD38 CD123
2 2 60 47 46 15 6 3 34 33
2.2 2.2 67.4 52.8 51.7 16.9 6.7 3.4 38.2 37.1
0 0 27 14 14 0 4 1 11 10
0 0 81.8 42.4 42.4 0 12.1 3.0 33.3 30.3
than that of NPM1-negative patients. Furthermore, they also found that NPM1-positive AML with monocytic or myeloid involvement exhibits distinct immunophenotype [5]. In conclusion, both methods have their advantages and disadvantages. FCM could be a complementary method to MRD monitoring for AML patients with NPM1 mutation.
Ann Hematol Funding information The work was supported by the National Natural Science Foundation of China (grant no. 81670175, grant no. 81870137).
Compliance with ethical standards
3.
Conflict of interest The authors declare that they have
Data Loading...
